Development of Smart Polymer Microparticles through Suspension Polymerization for Treatment of Schistosomiasis

Schistosomiasis is a parasitic disease that affects millions of people, especially low‐income people, and is considered a major public health problem in underdeveloped countries. The drug used most often for the treatment of the disease is praziquantel (PZQ), which has a strong and characteristic bitter taste that makes treatment of children inconvenient. For this reason, the present work investigates the development of smart pH‐sensitive polymer microparticles produced through suspension polymerizations to be used as vehicles for the controlled release of praziquantel in the body. The microparticles are produced through copolymerization of methyl methacrylate and the cationic comonomers diethylaminoethyl methacrylate or dimethylaminoethyl methacrylate. The obtained results indicate that microparticles with sizes in the range of 10–1100 µm can be formed successfully, allowing high PZQ encapsulation efficiencies (>80%). Zeta potential analyses and drug release assays confirm the pH‐sensitive responses of the cationic copolymers, leading to effective release of PZQ (around 80% in pH 1.2) in acidic media that simulate the organic fluids present in the stomach. pH‐sensitive smart microparticles are produced through free‐radical suspension copolymerizations of methyl methacrylate, dimethylaminoethyl methacrylate, and diethylaminoethyl methacrylate for use as vehicles for the controlled release of praziquantel. The scenario is promising for oral applications of the obtained copolymer microparticles, because the gastrointestinal tract presents different pH ranges.